In a filing, Day One Biopharmaceuticals Inc revealed its HEAD OF R&D Blackman Samuel C. unloaded Company’s shares for reported $0.16 million on Mar 25 ’24. In the deal valued at $16.01 per share,10,000 shares were sold. As a result of this transaction, Blackman Samuel C. now holds 1,184,662 shares worth roughly $17.26 million.
Then, Blackman Samuel C. sold 30,000 shares, generating $457,314 in total proceeds. Upon selling the shares at $15.24, the HEAD OF R&D now owns 1,194,662 shares.
Before that, Blackman Samuel C. sold 20,000 shares. Day One Biopharmaceuticals Inc shares valued at $322,166 were divested by the HEAD OF R&D at a price of $16.11 per share. As a result of the transaction, Blackman Samuel C. now holds 1,224,662 shares, worth roughly $17.84 million.
BofA Securities downgraded its Day One Biopharmaceuticals Inc [DAWN] rating to an Underperform from a a Buy in a research note published on April 25, 2023; the price target was decreased to $9 from $34. A number of analysts have revised their coverage, including CapitalOne’s analysts, who began to cover the stock in early February with a ‘”an Overweight”‘ rating. Oppenheimer began covering DAWN with “Perform” recommendation on February 03, 2023. H.C. Wainwright started covering the stock on December 15, 2022. It rated DAWN as “a Buy”.
Price Performance Review of DAWN
On Friday, Day One Biopharmaceuticals Inc [NASDAQ:DAWN] saw its stock jump 2.61% to $14.57. Over the last five days, the stock has lost -11.80%. Day One Biopharmaceuticals Inc shares have fallen nearly -0.21% since the year began. Nevertheless, the stocks have risen 15.45% over the past one year. While a 52-week high of $17.85 was reached on 03/01/24, a 52-week low of $9.67 was recorded on 01/19/24. SMA at 50 days reached $15.28, while 200 days put it at $13.37. A total of 0.52 million shares were traded, compared to the trading of 0.84 million shares in the previous session.
Levels Of Support And Resistance For DAWN Stock
The 24-hour chart illustrates a support level at 13.97, which if violated will result in even more drops to 13.38. On the upside, there is a resistance level at 14.95. A further resistance level may holdings at 15.34. The Relative Strength Index (RSI) on the 14-day chart is 44.64, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.37, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 69.42%. Stochastics %K at 37.18% indicates the stock is a holding.
How much short interest is there in Day One Biopharmaceuticals Inc?
A steep rise in short interest was recorded in Day One Biopharmaceuticals Inc stocks on Mar 15, 2024, dropping by -0.11 million shares to a total of 9.61 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 9.72 million shares. There was a decline of -1.14%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 17.35% of the overall stock float, the days-to-cover ratio (short ratio) fell to 13.25.
The most recent change occurred on December 14, 2022 when Needham began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
